TEST BANK For Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition by Woo & Wright, All 57 Chapters Covered,Latest Edition

TEST BANK
Pharmacotherapeutics for Advanced Practice Nurse
Prescribers 6e by Teri Moser Woo.

, Woo Pharmacotherapeutics`for` APN`Prescribers,`6e Ch01


Chapter`1.`The`Role`of`the`Advanced`Practice`Nurse`as`Prescriber


MULTIPLE`CHOICE

1. Nurse`practitioner`prescriptive`authority`is`regulated`by:
A. The`National`Council`of`State`Boards`of`Nursing
B. The`U.S.`Drug`Enforcement`Administration
C. The`State`Board`of`Nursing`for`each`state
D. The`State`Board`of`Pharmacy
ANS:` C PTS:` ` 1

2. The`benefits`to`the`patient`of`having`an`advanced`practice`registered`nurse`(APRN)`prescriber`i
nclude:
A. Nurses`know`more`about`pharmacology`than`other`prescribers`because`they`take`it`
both`in`their`basic`nursing`program`and`in`their`APRN`program.
B. Nurses`care`for`the`patient`from`a`holistic`approach`and`include`the`patient`in`
decision-making`regarding`their`care.
C. APRNs`are`less`likely`to`prescribe`narcotics`and`other`controlled`substances.
D. APRNs`are`able`to`prescribe`independently`in`all`states,`whereas`a`physician’s`
assistant`needs`to`have`a`physician`supervising`their`practice.
ANS:` B PTS:` ` 1

3. Clinical`judgment`in`prescribing`includes:
A. Factoring`in`the`cost`to`the`patient`of`the`medication`prescribed
B. Always`prescribing`the`newest`medication`available`for`the`disease`process
C. Handing`out`drug`samples`to`poor`patients
D. Prescribing`all`generic`medications`to`cut`costs
ANS:` A PTS:` ` 1

4. The`process`for`choosing`an`effective`drug`for`a`disorder`includes:
A. Asking`the`patient`what`drug`they`think`would`work`best`for`them
B. Consulting`nationally`recognized`guidelines`for`disease`management
C. Prescribing`medications`that`are`available`as`samples`before`writing`a`prescription
D. Following`U.S.`Drug`Enforcement`Administration`guidelines`for`prescribing
ANS:` B PTS:` ` 1

5. Nonintentional`nonadherence`of`drug`therapy`may`occur`due`to:
A. Belief`that`medication`does`not`work
B. Adverse`drug`reactions
C. Chronic`conditions`that`require`daily`therapy
D. Forgetfulness`or`distraction
ANS:` D PTS:` ` 1

, Woo 1
Pharmacotherapeutics`for`APN`Prescribers,` 6e Ch02


Chapter`2.`Review`of`Basic`Principles`of`Pharmacology


MULTIPLE`CHOICE

1. A`patient’s`nutritional`intake`and`laboratory`results`reflect`hypoalbuminemia.`This`is`critical`t
o`prescribing`because:
A. Distribution`of`drugs`to`target`tissue`may`be`affected.
B. The`solubility`of`the`drug`will`not`match`the`site`of`absorption.
C. There`will`be`less`free`drug`available`to`generate`an`effect.
D. Drugs`bound`to`albumin`are`readily`excreted`by`the`kidneys.
ANS:` A PTS:` ` 1

2. Drugs`that`have`a`significant`first-pass`effect:
A. Must`be`given`by`the`enteral`(oral)`route`only
B. Bypass`the`hepatic`circulation
C. Are`rapidly`metabolized`by`the`liver`and`may`have`little,`if`any,`desired`action
D. Are`converted`by`the`liver`to`more`active`and`fat-soluble`forms

ANS:` C PTS:` ` 1

3. The`route`of`excretion`of`a`volatile`drug`will`likely`be`the:
A. Kidneys
B. Lungs
C. Bile`and`feces
D. Skin
ANS:` B PTS:` ` 1

4. A`major`disadvantage`to`IV`administration`is`that:
A. First-pass`metabolism`is`eliminated.
B. Needles`and`sterility`are`required.
C. Absorption`of`the`drug`cannot`be`slowed`after`administration.
D. It`is`significantly`more`expensive`than`other`routes.
ANS:` C PTS:` ` 1

5. The`nurse`practitioner`(NP)`chooses`to`give`cephalexin`every`8`hours`based`on`knowledge`of`t
he`drug’s:
A. Propensity`to`go`to`the`target`receptor
B. Biological`half-life
C. Pharmacodynamics
D. Safety`and`side`effects
ANS:` B PTS:` ` 1

6. Deferasirox`is`a`chelating`agent`used`to`treat`iron`overload`by`binding`iron`to`render`it`
biologically`inactive.`This`is`best`characterized`as`a(n):

, Woo 2
Pharmacotherapeutics`for`APN`Prescribers,` 6e Ch02


A. Nonreceptor`mechanism
B. Partial`agonist
C. Full`agonist
D. Noncompetitive`antagonist
ANS:` A PTS:` ` 1

7. The`point`in`time`on`the`drug`concentration`curve`that`indicates`the`first`sign`of`a`therapeutic`
effect`is`the:
A. Minimum`adverse`effect`level
B. Peak`of`action
C. Onset`of`action
D. Therapeutic`range
ANS:` C PTS:` ` 1

8. Phenytoin`requires`that`a`trough`level`be`drawn.`Peak`and`trough`levels`are`done:
A. When`the`drug`has`a`wide`therapeutic`range
B. When`the`drug`will`be`administered`for`a`short`time`only
C. When`there`is`a`high`correlation`between`the`dose`and`saturation`of`receptor`sites
D. To`determine`if`a`drug`is`in`the`therapeutic`range
ANS:` D PTS:` ` 1

9. A`laboratory`result`indicates`that`the`peak`level`for`a`drug`is`above`the`minimum`toxic`
concentration.`This`means`that`the:
A. Concentration`will`produce`therapeutic`effects.
B. Concentration`will`produce`an`adverse`response.
C. Time`between`doses`must`be`shortened.
D. Duration`of`action`of`the`drug`is`too`long.
ANS:` B PTS:` ` 1

10. Drugs`that`are`receptor`agonists`may`demonstrate`what`property?
A. Irreversible`binding`to`the`drug`receptor`site
B. Up-regulation`with`chronic`use
C. Desensitization`or`down-regulation`with`continuous`use
D. Inverse`relationship`between`drug`concentration`and`drug`action

ANS:` C PTS:` ` 1

11. Drugs`that`are`receptor`antagonists,`such`as`beta`blockers,`may`cause:
A. Down-regulation`of`the`drug`receptor
B. An`exaggerated`response`if`abruptly`discontinued
C. Partial`blockade`of`the`effects`of`agonist`drugs
D. An`exaggerated`response`to`competitive`drug`agonists
ANS:` B PTS:` ` 1